154 related articles for article (PubMed ID: 15298478)
1. Hypoxic cells in tumors as a target for cancer therapy.
Gali-Muhtasib HU; Diab-Assef M; Haddadin MJ
J Med Liban; 2002; 50(4):175-9. PubMed ID: 15298478
[TBL] [Abstract][Full Text] [Related]
2. Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs.
Gali-Muhtasib HU; Haddadin MJ; Rahhal DN; Younes IH
Oncol Rep; 2001; 8(3):679-84. PubMed ID: 11295102
[TBL] [Abstract][Full Text] [Related]
3. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
[TBL] [Abstract][Full Text] [Related]
4. Quinoxaline 1,4-dioxides: hypoxia-selective therapeutic agents.
Diab-Assef M; Haddadin MJ; Yared P; Assaad C; Gali-Muhtasib HU
Mol Carcinog; 2002 Apr; 33(4):198-205. PubMed ID: 11933073
[TBL] [Abstract][Full Text] [Related]
5. New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents.
Ismail MM; Amin KM; Noaman E; Soliman DH; Ammar YA
Eur J Med Chem; 2010 Jul; 45(7):2733-8. PubMed ID: 20236735
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
7. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
[TBL] [Abstract][Full Text] [Related]
8. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
9. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
Ebbesen P; Pettersen EO; Gorr TA; Jobst G; Williams K; Kieninger J; Wenger RH; Pastorekova S; Dubois L; Lambin P; Wouters BG; Van Den Beucken T; Supuran CT; Poellinger L; Ratcliffe P; Kanopka A; Görlach A; Gasmann M; Harris AL; Maxwell P; Scozzafava A
J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
[TBL] [Abstract][Full Text] [Related]
10. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
Lee HH; Wilson WR; Denny WA
Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.
Urquiola C; Vieites M; Torre MH; Cabrera M; Lavaggi ML; Cerecetto H; González M; Cerain AL; Monge A; Smircich P; Garat B; Gambino D
Bioorg Med Chem; 2009 Feb; 17(4):1623-9. PubMed ID: 19162490
[TBL] [Abstract][Full Text] [Related]
12. Selective hypoxia-cytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N1,N4-dioxide derivatives.
Vieites M; Noblía P; Torre MH; Cerecetto H; Laura Lavaggi M; Costa-Filho AJ; Azqueta A; de Cerain AL; Monge A; Parajón-Costa B; González M; Gambino D
J Inorg Biochem; 2006 Aug; 100(8):1358-67. PubMed ID: 16698084
[TBL] [Abstract][Full Text] [Related]
13. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
14. Tumor hypoxia in cancer therapy.
Brown JM
Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
[TBL] [Abstract][Full Text] [Related]
15. [Effects of anticancer drugs and combination effects of anthracyclines on the hypoxic cells of head and neck cancer].
Fujii M; Ohno Y; Kanzaki J
Gan To Kagaku Ryoho; 1995 Apr; 22(5):647-52. PubMed ID: 7717716
[TBL] [Abstract][Full Text] [Related]
16. Targeting hypoxia cell signaling for cancer therapy.
Melillo G
Cancer Metastasis Rev; 2007 Jun; 26(2):341-52. PubMed ID: 17415529
[TBL] [Abstract][Full Text] [Related]
17. Hypoxic cytotoxic agents: a new approach to cancer chemotherapy.
Brown JM
Drug Resist Updat; 2000 Feb; 3(1):7-13. PubMed ID: 11498360
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs.
Siim BG; Atwell GJ; Anderson RF; Wardman P; Pullen SM; Wilson WR; Denny WA
J Med Chem; 1997 Apr; 40(9):1381-90. PubMed ID: 9135035
[TBL] [Abstract][Full Text] [Related]
19. Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib.
Kardosh A; Soriano N; Pyrko P; Liu YT; Jabbour M; Hofman FM; Schönthal AH
J Biomed Sci; 2007 Sep; 14(5):647-62. PubMed ID: 17440835
[TBL] [Abstract][Full Text] [Related]
20. MR guided cancer treatment system for an elevated therapeutic index - a macroscopic approach.
Myhr G
Med Hypotheses; 2008; 70(3):665-70. PubMed ID: 17765401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]